使用配对肝活检检查的代谢功能障碍相关的脂肪性肝病患者的组织学疾病进展
Dilara Turan Gokce1, Merve Ekelik1, Mesut Gumussoy1
1Departments of Gastroenterology.
European journal of gastroenterology & hepatology
|September 23, 2025
概括
代谢功能障碍相关的脂肪性肝病 (MASLD) 经常进展,近一半的患者表现出组织学变化. 高血压和高ALT水平预测MASLD患者的临床疾病恶化.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 胃肠病学 胃肠病学
- 代谢疾病 代谢疾病
背景情况:
- 与代谢功能障碍相关的脂肪性肝病 (MASLD) 是一个日益严重的健康问题.
- 了解MASLD的自然史和进展对于患者管理至关重要.
研究的目的:
- 为了评估MASLD患者的组织学变化随着时间的推移使用配对肝活检.
- 为了确定纤维化和临床疾病进展的预测因素.
- 为了将组织学进展与临床结果相关联.
主要方法:
- 一项单中心研究包括114名MASLD患者,至少有两次肝活检.
- 对肝脏活检进行分析,以检测组织学变化和纤维化.
- 临床结果和进展被监测了10年的中位数.
主要成果:
- 44%的患者表现出组织学进展,其中28例显示纤维化进展.
- 与代谢功能障碍相关的脂肪肝炎 (MASH) 的患病率从83%增加到90%.
- 高血压和高ALT水平被确定为临床进展的显著预测因素 (OR:分别为2.611和2.815).
结论:
- 患有MASLD,MASL和MASH的患者表现出疾病进展.
- 基线高血压和异常肝检测是MASLD临床恶化的关键预测因素.
- 对MASLD进展和风险因素的进一步研究是有必要的.
更多相关视频
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
1.6K
08:41Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
1.7K
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
185
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
185
Ultrasound II: Endoscopic Ultrasound and FibroScan
565
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
565
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
215
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
215
